ArticleBMC gastroenterology2026
Development and validation of machine learning models for predicting cancer-specific survival in colorectal signet ring cell carcinoma.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundColorectal signet ring cell carcinoma (CSRCC) is a rare subtype of colorectal cancer characterized by an exceptionally poor prognosis. Currently, accurate survival prediction models for CSRCC are lacking. This study aimed to investigate the clinical characteristics of CSRCC and to develop and compare multiple machine learning–based models for predicting cancer-specific survival (CSS).
methodsWe retrospectively analyzed data from CSRCC patients diagnosed between January 2000 and December 2021 in the SEER database. Patients were randomly assigned to training and test cohorts in a 7:3 ratio. Prognostic variables were identified using the Boruta algorithm and multivariate Cox regression. Six prediction models were constructed: CoxPH, Lasso regression, Random Forest, XGBoost, GBM, and DeepSurv. Model performance and clinical utility were assessed using C-index, AUC, Brier score, and DCA. Global and local interpretability analyses were performed for the best-performing model.
resultsA total of 5,163 patients were included, comprising 3,610 in the training set and 1,553 in the test set. The median survival was 21 months, with 1-, 3-, and 5-year CSS rates of 72.0%, 46.4%, and 40.1%, respectively. The random forest model achieved the best overall performance. In the training set, the C-index was 0.760; the 1-, 3-, and 5-year AUCs were 0.849, 0.866, and 0.883, respectively; and the Brier scores were 0.139, 0.153, and 0.142, respectively. In the test set, the C-index was 0.721; the AUCs were 0.784, 0.808, and 0.813; and the Brier scores were 0.156, 0.176, and 0.168, respectively. Variable importance analysis identified AJCC stage, summary stage, and tumor size as the most influential prognostic factors.
conclusionRandom Forest model excels in CSRCC CSS prediction, with robust generalization and clinical potential for individualized prognosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.